Brammer Bio is a CDMO serving companies seeking to develop and commercialize cell and gene therapies. Operating out of a 64,000 square-foot early clinical campus in Alachua, Florida, a 66,000 square-foot phase III and commercial cGMP viral vector manufacturing facility in Cambridge, Massachusetts and a 50,000 square-foot facility in Lexington, Massachusetts (operational in 2018), Brammer Bio has additional strategic locations throughout the US. With more than a decade of experience, Brammer Bio specializes in process and analytical development, clinical manufacturing, warehousing and distribution, commercial manufacturing and business development services.